1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.pneurobio.2011.04.010" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.pneurobio.2011.04.010</a>
Pages
347–359
Issue
4
Volume
94
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The emergence of designed multiple ligands for neurodegenerative disorders.
Publisher
An entity responsible for making the resource available
Progress in neurobiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-09
Subject
The topic of the resource
*Drug Design; *Ligands; Amyloid beta-Peptides/metabolism; Antiparkinson Agents/therapeutic use; Clinical Trials as Topic; Humans; Molecular Structure; Neurodegenerative Diseases/*drug therapy; Neuroprotective Agents/*therapeutic use
Creator
An entity primarily responsible for making the resource
Geldenhuys Werner J; Youdim Moussa B H; Carroll Richard T; Van der Schyf Cornelis J
Description
An account of the resource
The incidence of neurodegenerative diseases has seen a constant increase in the global population, and is likely to be the result of extended life expectancy brought about by better health care. Despite this increase in the incidence of neurodegenerative diseases, there has been a dearth in the introduction of new disease-modifying therapies that are approved to prevent or delay the onset of these diseases, or reverse the degenerative processes in brain. Mounting evidence in the peer-reviewed literature shows that the etiopathology of these diseases is extremely complex and heterogeneous, resulting in significant comorbidity and therefore unlikely to be mitigated by any drug acting on a single pathway or target. A recent trend in drug design and discovery is the rational design or serendipitous discovery of novel drug entities with the ability to address multiple drug targets that form part of the complex pathophysiology of a particular disease state. In this review we discuss the rationale for developing such multifunctional drugs (also called designed multiple ligands or DMLs), and why these drug candidates seem to offer better outcomes in many cases compared to single-targeted drugs in pre-clinical studies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Examples are drawn from the literature of drug candidates that have already reached the market, some unsuccessful attempts, and others that are still in the drug development pipeline.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.pneurobio.2011.04.010" target="_blank" rel="noreferrer noopener">10.1016/j.pneurobio.2011.04.010</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Design
*Ligands
2011
Amyloid beta-Peptides/metabolism
Antiparkinson Agents/therapeutic use
Carroll Richard T
Clinical Trials as Topic
Geldenhuys Werner J
Humans
Molecular Structure
Neurodegenerative Diseases/*drug therapy
Neuroprotective Agents/*therapeutic use
Progress in neurobiology
Van der Schyf Cornelis J
Youdim Moussa B H